Cross-reactive antibodies induced by a monovalent influenza B virus vaccine

Influenza viruses related to the markedly antigenically divergent strains B/Yamagata/16/88 and B/Victoria/2/87 are circulating in human populations. Adults develop cross-reacting antibodies against recent and earlier influenza B virus strains after vaccination with B/Yamagata/16/88, probably because of previous influenza B virus infections or immunizations. Vaccines containing B/Yamagata/16/88 should adequately protect adults against B/Victoria/2/87 infections.

[1]  J. Wood,et al.  The hemagglutinin of influenza B virus present in clinical material is a single species identical to that of mammalian cell-grown virus. , 1990, Virology.

[2]  A. Kendal,et al.  Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. , 1990, Virology.

[3]  R. Henry,et al.  Improved colorimetric assay for detecting influenza B virus neutralizing antibody responses to vaccination and infection , 1989, Journal of clinical microbiology.

[4]  A. Kendal,et al.  Antibody response in humans to influenza virus type B host-cell-derived variants after vaccination with standard (egg-derived) vaccine or natural infection , 1988, Journal of clinical microbiology.

[5]  T. Cate,et al.  Increased sensitivity and reduced specificity of hemagglutination inhibition tests with ether-treated influenza B/Singapore/222/79 , 1983, Journal of clinical microbiology.

[6]  W. P. Glezen,et al.  Influenza B virus infections in the community and the family. The epidemics of 1976-1977 and 1979-1980 in Houston, Texas. , 1983, American journal of epidemiology.

[7]  A. Monto,et al.  Ether treatment of type B influenza virus antigen for the hemagglutination inhibition test , 1981, Journal of clinical microbiology.

[8]  Thomas Francis,et al.  EPIDEMIOLOGIC AND IMMUNOLOGIC SIGNIFICANCE OF AGE DISTRIBUTION OF ANTIBODY TO ANTIGENIC VARIANTS OF INFLUENZA VIRUS , 1953, The Journal of experimental medicine.

[9]  Recommended composition of influenza virus vaccines for use in the 1991-1992 season. , 1991, Releve epidemiologique hebdomadaire.

[10]  Recommended composition of influenza virus vaccines for use in the 1990-1991 season. , 1990, Releve epidemiologique hebdomadaire.

[11]  Prevention and control of influenza: Part I, Vaccines. , 1989, MMWR. Morbidity and mortality weekly report.

[12]  T. Francis,et al.  Influence of primary antigenic experience upon the development of a broad immunity to influenza. , 1957, Transactions of the Association of American Physicians.